WallStreetZenWallStreetZen

NASDAQ: EYPT
Eyepoint Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Eyepoint Pharmaceuticals revenue was $43.27M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $11.6M, up 10.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EYPT annual revenue was $43.3M, with -6% growth year-over-year.

EYPT past revenue growth

How has EYPT's revenue growth performed historically?

Company
-5.97%
Industry
437.31%
Market
20.27%
EYPT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
EYPT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
EYPT's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

EYPT revenue history

Current Revenue
$43.3M
Current Earnings
-$130.9M
Current Profit Margin
-302.4%

Be the first to know when EYPT announces revenue.

EYPT Revenue History By Year

EYPT Yearly RevenueEYPT RevenueEYPT ChangeEYPT Revenue Growth
2024-12-31$43.27M-$2.75M-5.97%
2023-12-31$46.02M$4.61M+11.14%
2022-12-31$41.40M$4.47M+12.09%
2021-12-31$36.94M$2.50M+7.27%
2020-12-31$34.44M$14.07M+69.10%
2019-12-31$20.37M$17.40M+587.77%
2018-06-30$2.96M-$4.58M-60.72%
2017-06-30$7.54M$5.92M+365.37%
2016-06-30$1.62M-$24.95M-93.90%
2015-06-30$26.57M$23.09M+664.90%
2014-06-30$3.47M$1.33M+62.06%
2013-06-30$2.14M-$1.38M-39.22%
2012-06-30$3.53M-$1.44M-28.98%
2011-06-30$4.97M-$18.09M-78.46%
2010-06-30$23.05M$10.89M+89.55%
2009-06-30$12.16M$8.69M+249.88%
2008-06-30$3.48M$1.69M+94.73%
2007-06-30$1.79M$749.00k+72.30%
2006-06-30$1.04M$909.64k+719.88%
2005-06-30$126.36k-$171.35k-57.56%
2004-06-30$297.71k$211.38k+244.87%
2003-06-30$86.33k-$628.62k-87.93%
2002-06-30$714.95kN/AN/A

1 of 2

Eyepoint Pharmaceuticals Revenue FAQ

What was EYPT's revenue last quarter?

On Invalid Date, Eyepoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 2024 revenue of $11.59 million up 17.39% year over year. In the same quarter last year, Eyepoint Pharmaceuticals's revenue was $14.03 million.

What was Eyepoint Pharmaceuticals's revenue in 2024?

Eyepoint Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $43.27 million, a 5.97% decrease year over year.

How much does Eyepoint Pharmaceuticals make in a day?

Based on Eyepoint Pharmaceuticals annual revenue for the past five years, EYPT makes an average of $110,723.84 per day.

What was Eyepoint Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Eyepoint Pharmaceuticals's revenue has grown -5.97% year over year. This is 443.27 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Eyepoint Pharmaceuticals's revenue in the past year totaled $43.27 million.

How much does Eyepoint Pharmaceuticals make in a year?

Eyepoint Pharmaceuticals's revenue by year for the past five years is:
  • Eyepoint Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $43.27 million, a 5.97% decrease year over year.
  • Eyepoint Pharmaceuticals's annual revenue for Dec 31, 2023 was $46.02 million, a 11.14% increase from 2022.
  • Eyepoint Pharmaceuticals's annual revenue for 2022 was $41.40 million, a 12.09% increase from 2021.
  • Eyepoint Pharmaceuticals's annual revenue for 2021 was $36.94 million, a 7.27% increase from 2020.
  • Eyepoint Pharmaceuticals's annual revenue for 2020 was $34.44 million, a 69.1% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.